Gomez-Zubiaur Alba, Andres-Lencina Juan Jose, Cabezas Víctor, Corredera Cristina, di Brisco Fabio, Ferrer Blanca, Rodriguez-Villa Ana, Subiabre-Ferrer Daniela, Valenzuela Cristian, Diez David Vega, Ricart Jose Maria
Trichology Unit, Ricart Medical Institute, Madrid and Valencia, Spain.
Pharmacy Unit, Ricart Medical Institute, Madrid and Valencia, Spain.
Int J Trichology. 2023 Jan-Feb;15(1):39-40. doi: 10.4103/ijt.ijt_78_21. Epub 2023 Apr 19.
Bicalutamide is a selective androgen receptor antagonist. To date, it has been used orally with good efficacy results, but not in mesotherapy. In our center, we assessed whether patients undergoing bicalutamide mesotherapy showed positive responses and tolerated the local administration of bicalutamide. Six premenopausal women, with a mean age of 35.7 years and clinical diagnosis of Olsen Grade II or III female androgenetic alopecia accompanied by significant seborrhea were treated with 1 ml bicalutamide 0.5% mesotherapy. Three monthly sessions were performed. A subtle improvement in hair density was described after the third session. The overall satisfaction of the patients with the treatment was 6.3, on a scale of 1-10. Premenopausal women require several therapeutic approaches to combat severe androgenetic alopecia. Our data showed that bicalutamide mesotherapy was well tolerated and welcomed by the patients; we, therefore, provide a new tool for the management of this pathology.
比卡鲁胺是一种选择性雄激素受体拮抗剂。迄今为止，它一直口服使用，疗效良好，但尚未用于中胚层疗法。在我们中心，我们评估了接受比卡鲁胺中胚层疗法的患者是否有积极反应以及是否耐受比卡鲁胺的局部给药。六名绝经前女性，平均年龄35.7岁，临床诊断为奥尔森II级或III级女性雄激素性脱发并伴有明显皮脂溢出，接受了1毫升0.5%比卡鲁胺中胚层疗法治疗。共进行了三个月的疗程。第三次治疗后，头发密度有细微改善。患者对治疗的总体满意度为6.3分（满分10分）。绝经前女性需要多种治疗方法来对抗严重的雄激素性脱发。我们的数据表明，比卡鲁胺中胚层疗法耐受性良好且受到患者欢迎；因此，我们为这种病症的治疗提供了一种新工具。
